サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1390602

ファーマコゲノミクス市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Pharmacogenomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 147 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ファーマコゲノミクス市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月24日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のファーマコゲノミクス市場規模は2022年に73億米ドルに達しました。今後、IMARC Groupは、2022年から2028年にかけて9.08%の成長率（CAGR）を示し、2028年までに123億米ドルに達すると予測しています。

ファーマコゲノミクスは、特定の薬物に対するヒト遺伝子の遺伝的変異の研究です。薬理学とゲノミクスの原理を利用し、個人の遺伝子構成に合わせた効果的で安全な医薬品を開発します。ポリメラーゼ連鎖反応（PCR）、マイクロアレイ、デオキシリボ核酸（DNA）シークエンシング、質量分析、電気泳動など、さまざまな技術が用いられます。薬理ゲノミクスで行われる遺伝子検査は、特定の疾患に対する感受性や新しく開発された薬剤の有効性を判定するのに役立ちます。ファーマコゲノミクスは、心血管、アルツハイマー、がん、ヒト免疫不全ウイルス・後天性免疫不全症候群（HIV/AIDS）、喘息など、さまざまな疾患の治療にも広く利用されています。

ファーマコゲノミクス市場の動向：

世界中の製薬業界の著しい成長は、市場の見通しを明るくする重要な要因の1つです。さらに、医薬品の安全性を高めた精密医薬品に対する需要の高まりが、市場の成長を後押ししています。慢性的な生活習慣病の増加に伴い、副作用を最小限に抑え、有効性を向上させた標的薬物療法の採用が広がっています。これに伴い、ファーマコゲノミクスはがん治療にも広く利用され、化学療法薬や標的免疫生物学的製剤の薬剤反応、耐性、有効性、毒性の可能性を予測し、これも市場成長に寄与しています。さらに、薬理ゲノムバイオマーカー標識ソリューションの開発など、さまざまな技術的進歩も成長を促す要因となっています。これらは、体内で回避可能な薬物有害反応（ADR）のリスクを最小限に抑え、臨床転帰を改善するのに役立ちます。その他の要因としては、広範な研究開発（R&D）活動、ヘルスケアインフラの大幅な改善などが挙げられ、市場の成長を後押しすると予想されます。

本レポートで扱う主な質問

  • 世界のファーマコゲノミクス市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界のファーマコゲノミクス市場に与えた影響は？
  • 主要な地域市場は？
  • 技術別の市場内訳は？
  • 用途別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のファーマコゲノミクス市場の構造と主要プレーヤーは？
  • 業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のファーマコゲノミクス市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：技術別

  • ポリメラーゼ連鎖反応
    • 市場動向
    • 市場予測
  • マイクロアレイ
    • 市場動向
    • 市場予測
  • DNAシーケンス
    • 市場動向
    • 市場予測
  • 質量分析
    • 市場動向
    • 市場予測
  • 電気泳動
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • オンコロジー
    • 市場動向
    • 市場予測
  • 感染症領域
    • 市場動向
    • 市場予測
  • 循環器疾患
    • 市場動向
    • 市場予測
  • 神経疾患
    • 市場動向
    • 市場予測
  • 精神医学
    • 市場動向
    • 市場予測
  • 疼痛管理
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院・クリニック
    • 市場動向
    • 市場予測
  • 学術・研究機関
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • AstraZeneca plc
    • Bayer AG
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Illumina Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Myriad Genetics Inc.
    • Qiagen N.V.
    • Thermo Fisher Scientific Inc
図表

List of Figures

  • Figure 1: Global: Pharmacogenomics Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacogenomics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Pharmacogenomics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Pharmacogenomics Market: Breakup by Technology (in %), 2022
  • Figure 5: Global: Pharmacogenomics Market: Breakup by Application (in %), 2022
  • Figure 6: Global: Pharmacogenomics Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Pharmacogenomics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Pharmacogenomics (Polymerase Chain Reaction) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Pharmacogenomics (Polymerase Chain Reaction) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Pharmacogenomics (Microarray) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Pharmacogenomics (Microarray) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Pharmacogenomics (DNA Sequencing) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Pharmacogenomics (DNA Sequencing) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Pharmacogenomics (Mass Spectrometry) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Pharmacogenomics (Mass Spectrometry) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Pharmacogenomics (Electrophoresis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Pharmacogenomics (Electrophoresis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Pharmacogenomics (Other Technologies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Pharmacogenomics (Other Technologies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Pharmacogenomics (Oncology) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Pharmacogenomics (Oncology) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Pharmacogenomics (Infectious Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Pharmacogenomics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Pharmacogenomics (Cardiovascular Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Pharmacogenomics (Cardiovascular Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Pharmacogenomics (Neurological Diseases) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Pharmacogenomics (Neurological Diseases) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Pharmacogenomics (Psychiatry) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Pharmacogenomics (Psychiatry) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Pharmacogenomics (Pain Management) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Pharmacogenomics (Pain Management) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Pharmacogenomics (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Pharmacogenomics (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Pharmacogenomics (Hospitals and Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Pharmacogenomics (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Pharmacogenomics (Academic and Research Institutes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Pharmacogenomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: North America: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: North America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: United States: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: United States: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Canada: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Canada: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Asia-Pacific: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Asia-Pacific: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: China: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: China: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Japan: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Japan: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: India: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: India: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: South Korea: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: South Korea: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Australia: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Australia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Indonesia: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Indonesia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Europe: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Europe: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Germany: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Germany: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: France: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: France: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: United Kingdom: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: United Kingdom: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Italy: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Italy: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Spain: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Spain: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Russia: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Russia: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Latin America: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Latin America: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Brazil: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Brazil: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Mexico: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Mexico: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Others: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Others: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Middle East and Africa: Pharmacogenomics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Middle East and Africa: Pharmacogenomics Market: Breakup by Country (in %), 2022
  • Figure 86: Middle East and Africa: Pharmacogenomics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Global: Pharmacogenomics Industry: SWOT Analysis
  • Figure 88: Global: Pharmacogenomics Industry: Value Chain Analysis
  • Figure 89: Global: Pharmacogenomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacogenomics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pharmacogenomics Market Forecast: Breakup by Technology (in Million US$), 2023-2028
  • Table 3: Global: Pharmacogenomics Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 4: Global: Pharmacogenomics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Pharmacogenomics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Pharmacogenomics Market: Competitive Structure
  • Table 7: Global: Pharmacogenomics Market: Key Players
目次
Product Code: SR112023A4396

Abstract

The global pharmacogenomics market size reached US$ 7.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.08% during 2022-2028.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacogenomics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, application and end user.

Breakup by Technology:

Polymerase Chain Reaction

Microarray

DNA Sequencing

Mass Spectrometry

Electrophoresis

Others

Breakup by Application:

Oncology

Infectious Diseases

Cardiovascular Diseases

Neurological Diseases

Psychiatry

Pain Management

Others

Breakup by End User:

Hospitals and Clinics

Academic and Research Institutes

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global pharmacogenomics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pharmacogenomics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pharmacogenomics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacogenomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Polymerase Chain Reaction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Microarray
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Sequencing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mass Spectrometry
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Electrophoresis
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infectious Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neurological Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Psychiatry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Pain Management
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Academic and Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GlaxoSmithKline plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Illumina Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Myriad Genetics Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Qiagen N.V.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Thermo Fisher Scientific Inc
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis